BofA lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $8 from $10 and keeps a Buy rating on the shares, citing an updated cash position following the company’s Q3 update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
- Buy Rating for Rocket Pharmaceuticals: Strategic Progress and Strong Financial Position Drive Positive Outlook
- Rocket Pharmaceuticals Reports Q3 2025 Financial Results
- Rocket Pharmaceuticals reports Q3 EPS (45c), consensus (52c)
- RCKT Upcoming Earnings Report: What to Expect?